Topic Collection

Chronic kidney disease (CKD) represents a particularly challenging complication of diabetes, occurring in approximately 30-40% of patients with diabetes. The presence of CKD complicates overall diabetes management and is associated with increased risks for poor kidney, heart, and mortality outcomes. Fortunately for patients with diabetic kidney disease (DKD), recent therapeutic advancements offer treatments capable of addressing residual risk as an add-on to standard-of-care renin-angiotensin system (RAS) blockade to slow kidney disease progression and reduce cardiovascular and mortality risk. Recent approvals of agents from the sodium-glucose cotransporter-2 (SGLT2) inhibitor and nonsteroidal mineralocorticoid receptor antagonist classes to improve outcomes in patients with DKD has fuelled research efforts to better understand the pathophysiology of cardiorenal syndrome and how these and future therapies in development mitigate kidney, heart, and mortality risks. Furthermore, current evidence shows that many of the patients who could derive the most benefit from novel organ protective therapies are the least likely to receive them, thus necessitating the development of new care models to optimise use of guideline directed therapies in patients with DKD.

     

All submitted articles are subject to the journal's normal peer review process. The Editor in Chief is responsible for the content of this Topic Collection. Guest Editors will manage peer review, invite reviewers and make a recommendation, but the final decision on all manuscripts will be made by the Editor-in-Chief. For any inquiries regarding this topic collection, please contact topic.collections@bmj.com. Key words: Cardiorenal, Chronic kidney disease, Diabetes, Diabetic kidney disease, End-stage kidney disease, Finerenone, GLP-1 receptor agonists, Guideline directed medical therapy, Kidney outcomes, SGLT2 inhibitors, Team-based care

Effects of sodium-glucose cotransporter-2 (SGLT-2) inhibitors on serum uric acid levels in patients with chronic kidney disease: a systematic review and network meta-analysis (18 January 2024) Linli Zhang, Fan Zhang, Yan Bai, Liuyan Huang, Yifei Zhong, Xianwen Zhang Diabetes and chronic kidney disease in Chinese adults: a population-based cohort study (24 January 2024) Xue Wang, Lu Chen, Kexiang Shi, Jun Lv, Dianjianyi Sun, Pei Pei, Ling Yang, Yiping Chen, Huaidong Du, Jiaqiu Liu, Xiaoming Yang, Maxim Barnard, Junshi Chen, Zhengming Chen, Liming Li, Canqing Yu Role of perirenal adiposity in renal dysfunction among CKD individuals with or without diabetes: a Japanese cross-sectional study  (11 March 2024) Teruyuki Kono, Gulinu Maimaituxun, Hayato Tanabe, Moritake Higa, Haruka Saito, Kenichi Tanaka, Hiroaki Masuzaki, Masataka Sata, Junichiro J. Kazama, Michio Shimabukuro The case for a ketogenic diet in the management of kidney disease (27 April 2024) Shaminie J Athinarayanan, Caroline G P Roberts, Chandan Vangala, Greeshma K Shetty, Amy L McKenzie, Thomas Weimbs, Jeff S Volek Multidisciplinary proactive e-consults to improve guideline-directed medical therapies for patients with diabetes and chronic kidney disease: an implementation study (6 May 2024) Sharon Rikin, Laurie Bauman, Ivelina Arnaoudova, Katherine DiPalo, Nisha Suda, Sonali Gupta, Yuting Deng, Ladan Golestaneh